Hypertrophic Cardiomyopathy Clinical Trial

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of HCM
Presence of LVOT obstruction
Presence of symptoms

Exclusion Criteria:

Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction
Evidence of LVEF <50% in prior 6 months
Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase)

Other protocol-defined Inclusion/Exclusion criteria apply.

Study is for people with:

Hypertrophic Cardiomyopathy

Phase:

Phase 3

Estimated Enrollment:

40

Study ID:

NCT06253221

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 54 Locations for this study

See Locations Near You

Local Institution - 0017
Birmingham Alabama, 35294, United States More Info
Site 0017
Contact
Local Institution - 0050
Phoenix Arizona, 85016, United States More Info
Site 0050
Contact
Local Institution - 0032
Los Angeles California, 90027, United States More Info
Site 0032
Contact
Local Institution - 0008
Los Angeles California, 90095, United States More Info
Site 0008
Contact
Local Institution - 0004
Oakland California, 94609, United States More Info
Site 0004
Contact
Local Institution - 0033
Palo Alto California, 94304, United States More Info
Site 0033
Contact
Local Institution - 0044
San Diego California, 92123, United States More Info
Site 0044
Contact
Local Institution - 0038
Aurora Colorado, 80045, United States More Info
Site 0038
Contact
Local Institution - 0031
Saint Petersburg Florida, 33701, United States More Info
Site 0031
Contact
Local Institution - 0053
Atlanta Georgia, 30322, United States More Info
Site 0053
Contact
Local Institution - 0013
Chicago Illinois, 60637, United States More Info
Site 0013
Contact
Riley Hospital for Children - Pediatric Cardiology
Indianapolis Indiana, 46202, United States More Info
John Parent, Site 0009
Contact
317-908-4944
Local Institution - 0043
Boston Massachusetts, 02115, United States More Info
Site 0043
Contact
University of Michigan - C.S. Mott Children's Hospital
Ann Arbor Michigan, 48109, United States More Info
Mark Russell, Site 0002
Contact
734-660-3431
Local Institution - 0037
Saint Louis Missouri, 63110, United States More Info
Site 0037
Contact
Local Institution - 0052
Morristown New Jersey, 07960, United States More Info
Site 0052
Contact
Local Institution - 0040
Bronx New York, 10467, United States More Info
Site 0040
Contact
Cohen Children's Medical Center of New York
New Hyde Park New York, 11042, United States More Info
Jeffrey Gossett, Site 0010
Contact
516-601-7291
Local Institution - 0024
New York New York, 10029, United States More Info
Site 0024
Contact
Local Institution - 0036
New York New York, 10032, United States More Info
Site 0036
Contact
Local Institution - 0015
Charlotte North Carolina, 28204, United States More Info
Site 0015
Contact
Local Institution - 0039
Durham North Carolina, 27705, United States More Info
Site 0039
Contact
Local Institution - 0019
Cincinnati Ohio, 45229, United States More Info
Site 0019
Contact
Local Institution - 0001
Cleveland Ohio, 44195, United States More Info
Site 0001
Contact
Local Institution - 0029
Columbus Ohio, 43205, United States More Info
Site 0029
Contact
Local Institution - 0030
Philadelphia Pennsylvania, 19104, United States More Info
Site 0030
Contact
Local Institution - 0005
Pittsburgh Pennsylvania, 15224, United States More Info
Site 0005
Contact
Local Institution - 0034
Memphis Tennessee, 38104, United States More Info
Site 0034
Contact
Local Institution - 0045
Austin Texas, 78712, United States More Info
Site 0045
Contact
Local Institution - 0054
Houston Texas, 77030, United States More Info
Site 0054
Contact
Local Institution - 0003
Salt Lake City Utah, 84113, United States More Info
Site 0003
Contact
Local Institution - 0012
Charlottesville Virginia, 22908, United States More Info
Site 0012
Contact
Local Institution - 0035
Madison Wisconsin, 53792, United States More Info
Site 0035
Contact
Local Institution - 0020
Sydney New South Wales, 2145, Australia More Info
Site 0020
Contact
Local Institution - 0042
Clayton Victoria, 3168, Australia More Info
Site 0042
Contact
Local Institution - 0028
Parkville Victoria, 3052, Australia
Local Institution - 0041
Edmonton Alberta, T6G 2, Canada More Info
Site 0041
Contact
Local Institution - 0046
Toronto Ontario, M5G 1, Canada More Info
Site 0046
Contact
Local Institution - 0022
Paris , 75015, France More Info
Site 0022
Contact
Local Institution - 0026
Pessac , 33604, France More Info
Site 0026
Contact
Local Institution - 0018
Berlin BE, 13353, Germany More Info
Site 0018
Contact
Local Institution - 0006
Munich BY, 80636, Germany More Info
Site 0006
Contact
Local Institution - 0047
Drimnagh D, D12 V, Ireland More Info
Site 0047
Contact
Local Institution - 0016
Firenze FI, 50100, Italy More Info
Site 0016
Contact
Local Institution - 0051
Genova GE, 16147, Italy More Info
Site 0051
Contact
Local Institution - 0027
Napoli , 80131, Italy More Info
Site 0027
Contact
Local Institution - 0014
Barcelona B, 8950, Spain More Info
Site 0014
Contact
Local Institution - 0021
Granada GR, 18014, Spain
Local Institution - 0048
Madrid M, 28007, Spain More Info
Site 0048
Contact
Local Institution - 0011
A Coruna , 15009, Spain
Local Institution - 0023
Madrid , 28041, Spain
Local Institution - 0025
Madrid , 28046, Spain More Info
Site 0025
Contact
Local Institution - 0049
Belfast BFS, BT12 , United Kingdom More Info
Site 0049
Contact
Local Institution - 0007
London , WC1N , United Kingdom More Info
Site 0007
Contact

How clear is this clinincal trial information?

Study is for people with:

Hypertrophic Cardiomyopathy

Phase:

Phase 3

Estimated Enrollment:

40

Study ID:

NCT06253221

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.